Table 2. Randomized clinical trials (including more than 100 pts) of platinum-based chemotherapy plus BSC vs. BSC in advanced NSCLC.
Authors | Cytotoxic drugs | No of pts drugs/BSC | MS (mos) drugs/BSC | P value |
---|---|---|---|---|
Rapp et al./1988 (5) | CAP | 198/53 | 5.7/3.9 | 0.05 |
Woods et al./1990 (6) | Vdp | 7.5/3.9 | 0.01 | |
Thongprasert et al./1999 (7) | IErP/MVdp | 189/98 | 6.0/2.5 | 0.006 |
Cullen et al./1999 (8) | MIP | 175/175 | 6.7/4.8 | 0.03 |
Spiro et al./2004 (9) | Cisplatin-based, MMC-Ifo-CDDP, MMC-VDS-CDDP, CDDP-VDS, CDDP-VNR | 364/361 | 8/5.7 | 0.01 |